Literature DB >> 31852645

[Effect of atorvastatin on LOX-1 and eNOS expression in collateral vessels of hypercholesterolemic rats].

Tang Yinjuan1, Wang Jianjun2, Guan Yinglu3, Cai Weijun3, Tang Weijun4, Luo Mingying5.   

Abstract

OBJECTIVE: To investigate the effect of atorvastatin on the expression of lectin- like oxLDL receptor 1 (LOX-1) and endothelial nitric oxide synthase (eNOS) in collateral vessels of hypercholesterolemic rats.
METHODS: Forty male SD rats were randomized equally into 4 groups: femoral ligation group (L), hypercholesterolemia + femoral ligation group (HL), hypercholesterolemia+atorvastatin+femoral ligation group (AL), and hypercholesterolemia+normal saline+femoral ligation group (NL). The rats in the latter 3 groups were fed atherogenic diet for 8 weeks. At the end of the 8 weeks, the rats were subjected to femoral artery ligation with or without intraperitoneal injection of atorvastatin (AL group) or saline (NL group). Two weeks later, all the rats were euthanized and the expressions of LOX-1 and eNOS in the collateral vessels were detected with immunofluorescence assay. In the in vitro experiment, cultured human umbilical vein endothelial cells (HUVECs) were transfected with LOX-1 siRNA followed by treatment with oxLDL and/or atorvastatin. The expressions of LOX-1 and eNOS in the cells were detected with realtime PCR and Western blotting, and the cellular NO production was examined with Griess assay.
RESULTS: The collateral vessels of rats with normal feeding expressed LOX-1, which was significantly increased in the collateral vessels of hypercholesterolemic rats; atorvastatin treatment significantly lowered LOX-1 expressions in the hypercholesterolemic rats. In normally fed rats, the growing collateral vessels exhibited strong eNOS expressions, which were lowered in hypercholesterolemic rats and enhanced after atorvastatin treatment. In the cell experiment, HUVECs with oxLDL treatment showed a high LOX-1 expression and a low eNOS expression, and atorvastatin treatment of the cells down-regulated LOX-1 and up-regulated eNOS expressions. Inhibition of LOX-1 mediated by a specific LOX-1 siRNA abolished the effect of oxLDL stimulation on eNOS expression in the cells.
CONCLUSIONS: Both hypercholesterolemia and oxLDL can induce endothelial dysfunction and impair collateral vessel growth via the LOX-1/eNOS pathway in rats, and atorvastatin treatment can restore the LOX-1/eNOS pathway to promote the growth of the collateral vessels, suggesting the potential of atorvastatin as a therapeutic agent to promote repair of collateral vessel injuries in ischemic diseases.

Entities:  

Keywords:  arteriogenesis; atorvastatin; endothelial cells; endothelial nitric oxide synthase; hypercholesterolemia; lectin-like oxLDL receptor 1; oxidized LDL

Mesh:

Substances:

Year:  2019        PMID: 31852645      PMCID: PMC6926091          DOI: 10.12122/j.issn.1673-4254.2019.11.01

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  30 in total

1.  Inhibition of LOX-1 by statins may relate to upregulation of eNOS.

Authors:  J L Mehta; D Y Li; H J Chen; J Joseph; F Romeo
Journal:  Biochem Biophys Res Commun       Date:  2001-12-14       Impact factor: 3.575

2.  Association between the dosage and duration of statin treatment with coronary collateral development.

Authors:  Irem Dincer; Aydan Ongun; Sibel Turhan; Cagdas Ozdol; Deniz Kumbasar; Cetin Erol
Journal:  Coron Artery Dis       Date:  2006-09       Impact factor: 1.439

Review 3.  Atherosclerosis.

Authors:  A J Lusis
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

Review 4.  Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

Review 5.  Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals.

Authors:  Hideki Katagiri; Tetsuya Yamada; Yoshitomo Oka
Journal:  Circ Res       Date:  2007-07-06       Impact factor: 17.367

6.  Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein.

Authors:  H Moriwaki; N Kume; T Sawamura; T Aoyama; H Hoshikawa; H Ochi; E Nishi; T Masaki; T Kita
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-10       Impact factor: 8.311

7.  Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.

Authors:  Emile R Mohler; William R Hiatt; Mark A Creager
Journal:  Circulation       Date:  2003-09-02       Impact factor: 29.690

8.  Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis.

Authors:  Masataka Sata; Hiroaki Nishimatsu; Jun-ichi Osuga; Kimie Tanaka; Nobukazu Ishizaka; Shun Ishibashi; Yasunobu Hirata; Ryozo Nagai
Journal:  Hypertension       Date:  2004-06       Impact factor: 10.190

9.  Berberine alleviates ox-LDL induced inflammatory factors by up-regulation of autophagy via AMPK/mTOR signaling pathway.

Authors:  Xiaodi Fan; Jun Wang; Jincai Hou; Chengren Lin; Alan Bensoussan; Dennis Chang; Jianxun Liu; Bing Wang
Journal:  J Transl Med       Date:  2015-03-15       Impact factor: 5.531

10.  Statin therapy reduces oxidized low density lipoprotein level, a risk factor for stroke outcome.

Authors:  Nai-Wen Tsai; Lian-Hui Lee; Chi-Ren Huang; Wen-Neng Chang; Ya-Ting Chang; Yu-Jih Su; Yi-Fang Chiang; Hung-Chen Wang; Ben-Chung Cheng; Wei-Che Lin; Chia-Te Kung; Chih-Min Su; Yu-Jun Lin; Cheng-Hsien Lu
Journal:  Crit Care       Date:  2014-01-14       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.